An overview of small-molecule inhibitors of VEGFR signaling

Laurent F. Hennequin, Elaine S. E. Stokes, Andrew P. Thomas, Craig Johnstone, Patrick A. Plé, Donald J. Ogilvie, Michael Dukes, Stephen R. Wedge, Jane Kendrew, Jon O. Curwen, Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors Journal of Medicinal Chemistry. ,vol. 45, pp. 1300- 1312 ,(2002) , 10.1021/JM011022E

Tomoko Takahashi, Hikaru Ueno, Masabumi Shibuya, VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells Oncogene. ,vol. 18, pp. 2221- 2230 ,(1999) , 10.1038/SJ.ONC.1202527

Michael J. Cross, Johan Dixelius, Taro Matsumoto, Lena Claesson-Welsh, VEGF-receptor signal transduction Trends in Biochemical Sciences. ,vol. 28, pp. 488- 494 ,(2003) , 10.1016/S0968-0004(03)00193-2

Marika J Karkkainen, Tatiana V Petrova, Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. ,vol. 19, pp. 5598- 5605 ,(2000) , 10.1038/SJ.ONC.1203855

Harold F. Dvorak, Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy Journal of Clinical Oncology. ,vol. 20, pp. 4368- 4380 ,(2002) , 10.1200/JCO.2002.10.088

D Strumberg, B Schultheis, I A Adamietz, O Christensen, M Buechert, J Kraetzschmar, P Rajagopalan, M Ludwig, A Frost, S Steinbild, M E Scheulen, K Mross, Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. British Journal of Cancer. ,vol. 99, pp. 1579- 1585 ,(2008) , 10.1038/SJ.BJC.6604724

Paul W. Manley, Pascal Furet, Guido Bold, Josef Brüggen, Jürgen Mestan, Thomas Meyer, Christian R. Schnell, Jeanette Wood, Martin Haberey, Andreas Huth, Martin Krüger, Andreas Menrad, Eckhard Ottow, Dieter Seidelmann, Gerhard Siemeister, Karl-Heinz Thierauch, Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors Journal of Medicinal Chemistry. ,vol. 45, pp. 5687- 5693 ,(2002) , 10.1021/JM020899Q

Stephen Boyer, Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Current Topics in Medicinal Chemistry. ,vol. 2, pp. 973- 1000 ,(2002) , 10.2174/1568026023393273

Napoleone Ferrara, Robert S Kerbel, None, Angiogenesis as a therapeutic target Nature. ,vol. 438, pp. 967- 974 ,(2005) , 10.1038/NATURE04483

Charles J. Ryan, Walter M. Stadler, Bruce Roth, Douglass Hutcheon, Shauna Conry, Thomas Puchalski, Charles Morris, Eric J. Small, Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Investigational New Drugs. ,vol. 25, pp. 445- 451 ,(2007) , 10.1007/S10637-007-9050-Y